NMS·Healthcare·$138M·#457 / 520 in Healthcare
IPHA Innate Pharma S.A.
22HIGH RISK
CATEGORY BREAKDOWN
GROWTH0
QUALITY0
STABILITY55
VALUATION26
GOVERNANCE20
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-77.9%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
10 months
32
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
-104.0%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
15.3x
26
< 3x strong
Rule of 40
Growth rate plus operating margin
-1995
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
1.7%
13
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+11.9%
34
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE IPHA WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when IPHA's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.